Perficient: Drug Development

APRIL 10, 2025

Welcome to our new series on Universal Design for Pharmacies! In this segment, well explore the importance of Universal Design in Pharmacies for All Disabilities. As pharmacies continue to expand their digital presence, providing services through websites and mobile platforms, ensuring accessibility is crucial.

Pharmacy 52

Pharmacy Compliance Regulations 52

Alta Sciences

DECEMBER 14, 2023

A Closer Look At Our On-Site Compounding Pharmacies shajjar Thu, 12/14/2023 - 21:30 HTML Altasciences' dedicated pharmacists bring a wealth of expertise in controlled substances and complex compounding, ensuring maximum precision and safety standards. Electronic security access to the pharmacy and video monitoring. -

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

Agency IQ

SEPTEMBER 15, 2023

BY AMANDA CONTI SEP 13, 2023 1:58 PM CDT Quick background on nonprescription drug regulation Nonprescription drugs, also known as over-the-counter (OTC) drugs, are regulated differently than traditional prescription drugs. The FDA will follow these procedures for both agency-initiated operations (e.g.,

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

Alta Sciences

MAY 16, 2025

At the time, GLP regulations were becoming more enforceable, studies conducted with a casual adherence, i.e., in the spirit, to GLPs were viewed as retrospectively inadequate and would no longer fly with the standards required by the FDA, Environmental Protection Agency (EPA) and other regulatory bodies.

Laboratories 52

Laboratories Science Pharmaceuticals Pharmacy 52

Agency IQ

FEBRUARY 12, 2024

Under the FDA’s Good Guidance Practices regulation at 21 CFR 10.115 , the agency is required to annually publish “a list of possible topics for future guidance document development or revision during the next year.” Our review found that CDER is planning several notable new guidances, including one on artificial intelligence.

Biosimilars 40

Biosimilars Science Clinical Pharmacology FDA 40

Agency IQ

FEBRUARY 15, 2024

CDRH FY2024 Guidance Agenda Clinical application Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma CBER Final By 12/31/24 CBER CY 2024 Guidance Agenda Blood Considerations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method CBER Draft (..)

FDA 40

FDA Science Biosimilars Clinical Trials 40

Drug & Device Law

FEBRUARY 20, 2023

In updating chapter three of his book , on non-informational causes of action, Bexis had the opportunity to add the last several years of “alternative design” opinions. In at least the short term, a popular pain reliever would have to be removed from pharmacies. This would run counter to. . . 2d at 571.

FDA 59

FDA FDA Approval Testimonials Vaccine 59